People: Corcept Therapeutics Inc (CORT.PH)

Summary

Name	Age	Since	Current Position
James Wilson	68	1999	Chairman of the Board
Robert Roe	72	2003	President, Secretary
Joseph Belanoff	55	1999	Chief Executive Officer, Director
Gary Robb	50	2011	Chief Financial Officer
Anne LeDoux	65	2007	Vice President, Chief Accounting Officer, Controller
Steven Lo	45	2010	Vice President - Commercial Operations
G. Leonard Baker	69	1999	Independent Director
Daniel Bradbury	51	2012	Independent Director
Joseph Cook	70	2002	Independent Director
Patrick Enright	50	2008	Independent Director
David Mahoney	58	2004	Independent Director
Joseph Turner	61	2010	Independent Director

» Insider Trading

Biographies

Name	Description
James Wilson	Mr. James N. Wilson is Chairman of the Board of Corcept Therapeutics Inc., since 1999. In addition, since 2005, Mr. Wilson has been the Chairman of the Board of NuGEN Technologies, Inc., a provider of systems for genomic analysis. From 2002 to 2009, he served as the lead independent director of Amylin Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and from 1996 to 2001 Mr. Wilson was Chairman of the Board of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, he was Chief Operating Officer of Syntex Corporation, which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr. Wilson was Chairman and Chief Executive Officer of Neurex Corporation, which was acquired by Elan Corporation plc, and from 1982 to 1988, Mr. Wilson was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr. Wilson received his B.A. and M.B.A. from the University of Arizona.
Robert Roe	Dr. Robert L. Roe, M.D., is President and Secretary of Corcept Therapeutics Inc. He joined the Company as President in October 2001. Dr. Roe has spent more than 35 years in the pharmaceutical and biotechnology industries. From 1999 to 2001, he served as President and Chief Executive Officer of Allergenics, Inc. From 1996 to 1999, he was Executive Vice President, Chief Operating Officer and a director of Cytel Corporation. From 1995 to 1996, he was Executive Vice President, Chief Operating Officer and a director of Chugai Biopharmaceuticals, Inc. From 1992 to 1995, Dr. Roe served as President of the Development Research Division and Senior Vice President of Syntex Corporation. Dr. Roe received his B.A. from Stanford University and his M.D. from the University of California, San Francisco.
Joseph Belanoff	Dr. Joseph K. Belanoff, M.D., is Chief Executive Officer, Director of Corcept Therapeutics Inc., since 1999. Dr. Belanoff is a co-founder of company. Dr. Belanoff is currently a clinical faculty member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. From 1997 to 2001, he served as the Director of Psychopharmacology at the outpatient division of the Palo Alto Veterans Affairs Hospital. Dr. Belanoff received his B.A. from Amherst College and his M.D. from Columbia University’s College of Physicians & Surgeons. Dr. Belanoff also has experience in clinical medicine and psychopharmacology.
Gary Robb	Mr. Gary (Charlie) Charles Robb is Chief Financial Officer of Corcept Therapeutics Inc, since September 1, 2011. Mr. Robb has more than 25 years of experience in executive management, operations and finance. From April 2005 through August 2011 Mr. Robb served as the Senior Vice President of Operations, Administration and Finance of Fitness Anywhere, Inc. (FAI), a private fitness equipment and training company with operations in the United States, Europe and Asia. From 2003 to 2005, Mr. Robb was engaged in the private practice of law. From 2000 to 2002 he was Senior Vice President of Citadon, Inc. He also held positions in business development for Normura Asset Capital Corporation from 1998 to 1999 and in sales and marketing for Legal Research Network, Inc. from 1996 to 1998. From 1992 to 1996 Mr. Robb practiced law at Howard, Rice, Nemerovski, Canady, Falk & Rabkin. Mr. Robb earned a Bachelor of Arts in English and Political Philosophy from Yale University and a Juris Doctor from Harvard Law School, where he was a member of the Harvard Law Review.
Anne LeDoux	Ms. Anne M. LeDoux is Vice President, Chief Accounting Officer, Controller of Corcept Therapeutics Inc., since April 2007. She joined the company as Controller in 2004. Ms. LeDoux has over 15 years of financial and accounting management experience with public pharmaceutical and biotechnology companies. Prior to joining Corcept in 2004, Ms. LeDoux served in various financial positions at Aviron, Roche Biosciences and Syntex Corporation. She was also Vice President and Chief Financial Officer at the Northern California Health Center and Vice President, Finance for the Children’s Hospital of San Francisco. Ms. LeDoux is a Certified Public Accountant and has over 13 years of experience in public accounting, primarily at Coopers and Lybrand. Ms. LeDoux received her Bachelor of Arts degree in Business from the University of Massachusetts and a law degree from Western New England College, School of Law.
Steven Lo	Mr. Steven Lo is Vice President - Commercial Operations of Corcept Therapeutics Inc., since September 2010. Mr. Lo brings more than 15 years of commercial experience in the pharmaceutical and biotechnology industry. From 1997 to 2010, Mr. Lo held various positions in marketing, sales and managed markets at Genentech, Inc., a biotechnology company that became a member of the Roche Group in March in 2009, most recently as Franchise Head, that company’s endocrinology marketing and sales organization. Mr. Lo received his B.S. degree from the University of California, Davis and his Master of Health Administration from the University of Southern California.
G. Leonard Baker	Mr. G. Leonard Baker, Jr. is Independent Director of Corcept Therapeutics Inc., since 1999. Since 1973, Mr. Baker has been a Managing Director of the General Partner of Sutter Hill Ventures, a venture capital firm in Palo Alto, CA. Mr. Baker currently serves on the boards of Youku Inc. and a number of private companies. During the past five years Mr. Baker has served on the board of Therma-Wave, Inc., which was acquired in 2007 by KLA-Tencor Corporation. Mr. Baker is a fellow of the Yale Corporation and a board member of the Environmental Defense Fund. Mr. Baker received his B.A. from Yale University and his M.B.A. from Stanford University.
Daniel Bradbury	Mr. Daniel M. Bradbury has been appointed as Independent Director of Corcept Therapeutics Inc., effective 10 October 2012. Mr. Bradbury's career in the biotechnology and pharmaceutical industry spans 30 years. He served as Chief Executive Officer of Amylin Pharmaceuticals, Inc. from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. From June 2006 until August 2012 he was a member of Amylin's board of directors and served on its Finance and Risk Management Committee. Mr. Bradbury also served as Amylin's President (2006-2007), Chief Operating Officer (2003-2006) and Executive Vice President (2000-2003). From 1994-2003 he held a variety of sales and marketing positions at the company. Before joining Amylin, Mr. Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He also serves on the board of directors of Illumina, Inc., Geron Corporation and Castle Biosciences, Inc., the board of trustees of the Keck Graduate Institute, the Investor Growth Capital Advisory Board, and the BioMed Ventures Advisory Committee. Mr. Bradbury currently serves on the University of California San Diego's Rady School of Management's Advisory Council, the RAND Health Board of Advisors and the University of Miami's Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
Joseph Cook	Mr. Joseph C. Cook, Jr., is Independent Director of Corcept Therapeutics Inc., since 2002. Mr. Cook is a founder and director of Ironwood Pharmaceuticals, Inc., a publicly traded biotechnology company, and served as Chairman of its Board from 1998 to 2010. Mr. Cook is a principal, director and co-founder of Mountain Group Capital, LLC, a private investment company, and a principal, director and founder of The Limestone Fund, a recipient of the State of Tennessee TNInvestco award. He is a founder and serves as chairman of the board of Clinical Products, a private company marketing a medical food for people with diabetes. Mr. Cook served as chairman of Amylin Pharmaceuticals, Inc. from 1998 to 2009 and was chief executive officer from 1998 to 2003. He spent 28 years at Eli Lilly and Co., or Lilly, retiring in 1993 as a Group Vice-President. In 2009, Mr. Cook received the Pinnacle Award for Life Science Leadership from the Rady School of Management at the University of California at San Diego. In 1999, Mr. Cook also received The Nathan W. Dougherty Award for Distinguished Service in the Engineering Profession from the University of Tennessee. Mr. Cook received his B.S. in Engineering from the University of Tennessee in 1965.
Patrick Enright	Mr. Patrick G. Enright serves as Independent Director of Corcept Therapeutics Inc., since April 2008. He is a founder of Longitude Capital Management Co., LLC, a venture capital firm focused on investments in biotechnology and has served as its Managing Director since 2007. From 2002 through 2006, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately-held and publicly-traded biotechnology companies, such as SUGEN, Inc. and Cephalon, Inc. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. Mr. Enright also has life sciences operations experience. He was Chief Financial Officer and Senior Vice President Business Development of Valentis, Inc. (now Urigen Pharmaceuticals, Inc.) and Senior Vice President Finance and Business Development of Boehringer Mannheim Pharmaceuticals (now F. Hoffmann-La Roche. Ltd.). Mr. Enright began his life sciences career 24 years ago at Sandoz (now Novartis AG). He currently serves on the Boards of a number of privately-held companies, including Infacare Pharmaceutical Corporation and Xanodyne Pharmaceuticals, Inc., as well as Jazz Pharmaceuticals, Inc., a publicly traded pharmaceutical company. Within the last five years, Mr. Enright has served on the Boards of publicly-traded companies, including Threshold Pharmaceuticals, Inc., Sequenom, Inc., Valentis, Inc. (now Urigen Pharmaceuticals, Inc.), Codexis, Inc. and MAP Pharmaceuticals, Inc. Mr. Enright received his M.B.A. from the Wharton School of Business at the University of Pennsylvania and his B.S. in Biological Sciences from Stanford University.
David Mahoney	Mr. David L. Mahoney is Independent Director of Corcept Therapeutics Inc., since July 2004. From 1999 to 2001, Mr. Mahoney served as co-CEO of McKesson HBOC, Inc., a healthcare supply management and information technology company and as CEO of iMcKesson LLC, a healthcare management and connectivity company. He joined McKesson Corporation, or McKesson, in 1990 as Vice President for Strategic Planning. Prior to joining McKesson, Mr. Mahoney was a principal with McKinsey & Company, a management consulting firm, where he worked from 1981 to 1990. Mr. Mahoney serves on the Board of Symantec Corporation, a publicly-traded software technology company, including as a member of the Audit and Compensation Committees. He also serves on the Board of Directors of several privately-held organizations including Adamas Pharmaceuticals, Inc., 20x200.com, San Francisco Museum of Modern Art and Mercy Corps. Mr. Mahoney served on the Board of Tercica, Inc., a pharmaceutical company (acquired by the Ipsen Group), from 2004 through 2008, including as a member of the Audit and Compensation committees. Mr. Mahoney also served on the Board of Directors of non-profit organizations Live Oak School, and NCPB, Inc., a public television and radio operator. Mr. Mahoney received his B.A. from Princeton University and his M.B.A. from Harvard University.
Joseph Turner	Mr. Joseph L. Turner is Independent Director of Corcept Therapeutics Inc., since August 2010. Mr. Turner is a retired financial. Mr. Turner was Senior Vice President of Finance and Administration and Chief Financial Officer at Myogen, Inc., a therapeutics company focused on cardiovascular disease, from 1999 until its acquisition by Gilead Sciences, Inc. in November 2006. Prior to Myogen, Inc., he served as Vice President, Finance and Chief Financial Officer at Centaur Pharmaceuticals, Inc., a privately-held biopharmaceutical company, from 1997 to 1999 and as Vice President, Finance and Chief Financial Officer of Cortech, Inc. from 1992 to 1997. From 1979 to 1991, Mr. Turner worked at Lilly, where he held a variety of financial management positions both within the United States and abroad. Mr. Turner is currently a member of the Board of Directors of Alexza Pharmaceuticals, Inc., or Alexza, QLT, Inc., and Allos Therapeutics, Inc., publicly traded biotechnology companies. Mr. Turner serves as the Chair of the Audit and Ethics Committee of Alexza and is a member of the Audit and Risk Committee of QLT, Inc. He also serves on the Board of Directors of Kythera Biopharmaceuticals, Inc., a privately held pharmaceutical company. Mr. Turner also currently serves on the Board of Managers of Swarthmore College. Mr. Turner previously served on the Board of Directors and Audit Committee of SGX Pharmaceuticals, Inc., a publicly held biotechnology company that was acquired by Lilly, is a former director and Chairman of the Audit Committee of NovaCardia, Inc., a privately-held biotechnology company that was acquired by Merck & Co., Inc., and Sequel Pharmaceuticals, Inc., and served on the Board of Directors of ApopLogic Pharmaceuticals, Inc., a privately held biotechnology company. Mr. Turner received his M.B.A. from the University of North Carolina at Chapel Hill, an M.A. in Molecular Biology from the University of Colorado at Boulder and a B.A. in Chemistry from Swarthmore College.

Basic Compensation

Name	Fiscal Year Total
James Wilson	--
Robert Roe	1,576,840
Joseph Belanoff	3,524,110
Gary Robb	1,480,000
Anne LeDoux	609,415
Steven Lo	309,000
G. Leonard Baker	--
Daniel Bradbury	--
Joseph Cook	--
Patrick Enright	--
David Mahoney	--
Joseph Turner	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
James Wilson	0	0
Robert Roe	385,000	579,899
Joseph Belanoff	0	0
Gary Robb	0	0
Anne LeDoux	0	0
Steven Lo	0	0
G. Leonard Baker	0	0
Daniel Bradbury	0	0
Joseph Cook	0	0
Patrick Enright	0	0
David Mahoney	0	0
Joseph Turner	0	0

Insider Trading

Name	Shares Traded	Price
TURNER JOSEPH L	8,500	$2.01
TURNER JOSEPH L	1,500	$2.00
BAKER G LEONARD JR	5,600	$1.50
BAKER G LEONARD JR	1,400	$1.50
BAKER G LEONARD JR	4,200	$1.50
BAKER G LEONARD JR	12,931	$1.50
BAKER G LEONARD JR	14,500	$1.45
BAKER G LEONARD JR	3,500	$1.45
BAKER G LEONARD JR	34,000	$1.45
BAKER G LEONARD JR	11,000	$1.45
BRADBURY DANIEL M	99,000	$1.40
BRADBURY DANIEL M	80,000	$1.38
COXE TENCH C	572,519	$0.00
COXE TENCH C	572,519	$0.00
BAKER G LEONARD JR	100,000	$1.60
BAKER G LEONARD JR	100,000	$1.93
BAKER G LEONARD JR	100,000	$1.97
BAKER G LEONARD JR	205,232	$0.00
BAKER G LEONARD JR	205,232	$0.00
BAKER G LEONARD JR	482,906	$0.00
BAKER G LEONARD JR	482,906	$0.00
ROE ROBERT L	10,000	$1.19
ROE ROBERT L	10,000	$3.57
ROE ROBERT L	10,000	$4.23
ROE ROBERT L	10,000	$1.19

» Full list on Insider Trading

People: Corcept Therapeutics Inc (CORT.PH)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: